Using MRI scans to estimate liver cancer risk in cirrhosis patients
Tests whether detailed MRI scans, with blood and clinical data, predict liver cancer in cirrhosis.
Plain-language title generated from the registry record
Registry title: Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
Key facts
- Where
- Zhuhai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic liver disease at high risk of liver cancer. They need a special MRI scan and 5 years of follow-up data.
- Age
- Over 18 years old
- Sex
- All sexes can join
- Disease stage
- Chronic liver disease in the high-risk group for liver cancer (2022 Chinese guideline). Liver function Child-Pugh class A or B.
- Earlier treatment
- People who have had liver surgery cannot join.
- Biomarker or test result
- Needs a Gd-EOB-DTPA enhanced MRI scan with T1 mapping, T2 mapping, T2* mapping, T1ρ and other sequences. Needs 5-year follow-up data.
Main reasons for not taking part
- Cannot have an MRI scan, for example because of claustrophobia or abnormal kidney function
- Had liver surgery in the past
- Major diseases such as heart failure or tumors
Read by machine on 12 November 2026.
Where in China
- Yaqin, ZhangZhuhai, ChinaContact: Yaqin ZhangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Trial code
- NCT06060769
- Record updated
- 29 September 2023
- Original description
Quantitative MRI scanning parameters such as T1 mapping, T2 mapping, T1ρ, and elastography are used, combined with clinical and laboratory indicators, to predict the risk of liver cancer in patients with cirrhosis.Read full original descriptionShow less
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
Quantitative MRI scanning parameters such as T1 mapping, T2 mapping, T1ρ, and elastography are used, combined with clinical and laboratory indicators, to predict the risk of liver cancer in patients with cirrhosis.
Inclusion: 1. Aged over 18 years old; 2. Liver function Child-Pugh classification A or B; 3. Patients with chronic liver disease who meet the diagnostic criteria for high-risk groups of liver cancer in the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)"; 4. Equipped with Gd-EOB-DTPA enhanced MRI scan images, including T1 mapping, T2 mapping, T2* mapping, T1ρ and other sequences; 5. With 5-year follow-up data.
Exclusion: 1. Patients who are unable to undergo MRI scanning due to claustrophobia, abnormal renal function, etc.; 2. Patients who have undergone liver surgery in the past; 3. Patients with major diseases such as heart failure and tumors.